| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Unit of Endocrinology, Scientific Institute Casa Sollievo della Sofferenza (A.B., O.L., A.C., R.D.P., V.T.), San Giovanni Rotondo, Italy; Unit of Genetics, Scientific Institute Casa Sollievo della Sofferenza (A.Q., M.C.), San Giovanni Rotondo, Italy; Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud (F.P.), S. Maria Imbaro, Italy; Casa Sollievo della Sofferenza-Mendel Institute (S.P., V.T.), Rome, Italy; and Department of Clinical Sciences, University La Sapienza (V.T.), Rome, Italy
Address all correspondence and requests for reprints to: Dr. Angela Bulotta, Unit of Endocrinology, Scientific Institute Casa Sollievo della Sofferenza, Poliambulatorio Giovanni Paolo II, Viale Padre Pio, 71013 San Giovanni Rotondo (FG), Italy. E-mail: a.bulotta{at}operapadrepio.it.
Uncoupling protein-2 (UCP2) regulates insulin secretion and may play an important role in linking obesity to type 2 diabetes (T2D). Previous studies of the role of the UCP2 promoter 866G/A single nucleotide polymorphisms (SNP) in T2D have given opposite results. We tested the distribution of the 866G/A SNP in 746 T2D patients and 327 healthy unrelated Caucasians from Italy. We also tested for an effect of the P12A variant of the peroxisomal proliferator-activated receptor-
2 (PPAR
2) gene on diabetes risk given by the UCP2 SNP. Compared with 866G/G carriers, a progressively reduced (P = 0.01) risk of T2D was observed in 866G/A and 866A/A subjects, with the latter showing an approximately 50% risk reduction [odd ratio (OR), 0.51; 95% confidence interval (CI), 0.30.8; P = 0.003]. Conversely, the 866G/G genotype was associated with increased risk (OR, 1.31; 95% CI, 1.011.71). Overall, the population risk attributable to the UCP2 866G/G genotype was about 12%. After stratifying for the PPAR
2 polymorphism, the increased risk conferred by the UCP2 G/G genotype was still evident among P12/P12 homozygous subjects (n = 801; OR, 1.38; 95% CI, 1.041.83), but seemed to disappear among the X12/A12 subjects (i.e. P12/A12 heterozygous or A12/A12 homozygous subjects; n = 137; OR, 0.87; 95% CI, 0.401.91). Whether this apparent difference is entirely due to the different number of carriers of the two PPAR
2 genotypes is a likely possibility that deserves deeper investigation. In conclusion, in our population, the 866G/A SNP is associated with T2D. Additional studies in larger samples are needed to investigate the possibility of a concomitant effect of modifier genes such as PPAR
2.
This article has been cited by other articles:
![]() |
Y.-H. Hsu, T. Niu, Y. Song, L. Tinker, L. H. Kuller, and S. Liu Genetic Variants in the UCP2-UCP3 Gene Cluster and Risk of Diabetes in the Women's Health Initiative Observational Study Diabetes, April 1, 2008; 57(4): 1101 - 1107. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Chevillotte, M. Giralt, B. Miroux, D. Ricquier, and F. Villarroya Uncoupling Protein-2 Controls Adiponectin Gene Expression in Adipose Tissue Through the Modulation of Reactive Oxygen Species Production Diabetes, April 1, 2007; 56(4): 1042 - 1050. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Oberkofler, K. Klein, T. K. Felder, F. Krempler, and W. Patsch Role of Peroxisome Proliferator-Activated Receptor-{gamma} Coactivator-1{alpha} in the Transcriptional Regulation of the Human Uncoupling Protein 2 Gene in INS-1E Cells Endocrinology, February 1, 2006; 147(2): 966 - 976. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Yu, D. R. Jacobs Jr, P. J. Schreiner, M. D. Gross, M. W. Steffes, and M. Fornage The Uncoupling Protein 2 Ala55Val Polymorphism Is Associated with Diabetes Mellitus: The CARDIA Study Clin. Chem., August 1, 2005; 51(8): 1451 - 1456. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |